Thank you for sharing!

Your article was successfully shared with the contacts you provided.

In a 5-3 decision in FTC v. Actavis, the Supreme Court addressed the question of whether reverse settlement, or “pay for delay,” payments from an innovator drug company to a generic drugmaker to delay entry into the market constitute an antitrust violation. The court held that reverse payments are neither presumptively legal nor presumptively unlawful, and set out criteria for analyzing whether the payments were anticompetitive.

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.